Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GlcNAc-GlcN is a heterodisaccharide, specifically 4-O-(N-acetyl-β-D-glucosaminyl)-D-glucosamine, which is a product of chitin degradation. It is formed from N,N'-diacetylchitobiose ((GlcNAc)2) through the action of chitin oligosaccharide deacetylase (COD) or a combination of chitinase and COD. In various *Vibrio* bacteria, GlcNAc-GlcN acts as a crucial signaling molecule. It induces the production of chitinolytic enzymes, particularly chitinase, thereby enhancing the bacteria's ability to metabolize chitin. Furthermore, it functions as an effective chemoattractant for COD-producing *Vibrio* species and stimulates polar flagellum rotation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GlcNAc-GlcN.